A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer.

被引：0
|
作者：
Bryce, Alan Haruo
Karp, Daniel D.
Tagawa, Scott T.
Nordquist, Luke T.
Rathkopf, Dana E.
Adra, Nabil
Dorff, Tanya B.
Baeck, Johan
O'Donnell, Joseph Francis
Ames, Tyler David
Yim, Christina Y.
Price, Matthew
Scher, Howard I.
机构：
[1] Mayo Clin, Phoenix, AZ USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[3] Cornell Univ, Weill Cornell Med Coll, New York, NY USA
[4] Urol Canc Ctr PC, Omaha, NE USA
[5] Mem Sloan Kettering Canc Ctr, New York, NY USA
[6] Weill Cornell Med, New York, NY USA
[7] Indiana Univ, Simon Comprehens Canc Ctr, Indianapolis, IN USA
[8] City Hope Natl Med Ctr, Duarte, CA USA
[9] Promontory Therapeut Inc, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS292
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Long-term safety of darolutamide in patients with metastatic castration-resistant prostate cancer.
    Vjaters, Egils
    Fizazi, Karim
    James, Nicholas D.
    Tammela, Teuvo
    Matsubara, Nobuaki
    Priou, Frank
    Lesimple, Thierry
    Bono, Petri
    Kataja, Vesa V.
    Garcia, Jorge A.
    Protheroe, Andrew
    Aspegren, John
    Joensuu, Heikki
    Kuss, Iris
    Thiele, Silke
    Fiala-Buskies, Sabine
    Jones, Robert Hugh
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [22] Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer
    Masahiro Nozawa
    Hirofumi Mukai
    Shunji Takahashi
    Hiroji Uemura
    Takeo Kosaka
    Yusuke Onozawa
    Jun Miyazaki
    Kazuhiro Suzuki
    Koji Okihara
    Yoichi Arai
    Tomomi Kamba
    Masashi Kato
    Yasutomo Nakai
    Hiroshi Furuse
    Haruki Kume
    Hisamitsu Ide
    Hiroshi Kitamura
    Akira Yokomizo
    Takahiro Kimura
    Yoshihiko Tomita
    Keiji Ohno
    Yoshiyuki Kakehi
    International Journal of Clinical Oncology, 2015, 20 : 1026 - 1034
  • [23] Phase I study of entinostat in combination with enzalutamide for treatment of patients with castration-resistant prostate cancer.
    Lin, Jianqing
    Elkon, Jacob Matt
    Ricart, Brittany
    Burgess, Brooke
    Palmer, Erica
    Siegel, Robert S.
    Ma, Yan
    Villagra, Alejandro
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [24] Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer
    Nozawa, Masahiro
    Mukai, Hirofumi
    Takahashi, Shunji
    Uemura, Hiroji
    Kosaka, Takeo
    Onozawa, Yusuke
    Miyazaki, Jun
    Suzuki, Kazuhiro
    Okihara, Koji
    Arai, Yoichi
    Kamba, Tomomi
    Kato, Masashi
    Nakai, Yasutomo
    Furuse, Hiroshi
    Kume, Haruki
    Ide, Hisamitsu
    Kitamura, Hiroshi
    Yokomizo, Akira
    Kimura, Takahiro
    Tomita, Yoshihiko
    Ohno, Keiji
    Kakehi, Yoshiyuki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (05) : 1026 - 1034
  • [25] A phase 2 study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [26] A prospective phase I trial of dendritic cell-based cryoimmunotherapy in metastatic castration-resistant prostate cancer.
    Thomsen, Liv Cecilie Vestrheim
    Honore, Alfred
    Reisaeter, Lars Anders
    Almas, Bjarte
    Forde, Kristina
    Kristoffersen, Einar Kleboe
    Melve, Guro Kristin
    Biermann, Martin
    Helle, Svein Inge
    Azeem, Waqas
    Halvorsen, Ole Johan
    Akslen, Lars
    Bahn, Duke
    Pantel, Klaus
    Riethdorf, Sabine
    Ragde, Haakon
    Gjertsen, Bjorn T.
    Oyan, Anne Margrete
    Kalland, Karl-Henning
    Beisland, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Qualitative study to understand the emotional response to a metastatic diagnosis in castration-resistant prostate cancer.
    Burbridge, Claire
    Randall, Jason A.
    Symonds, Tara
    Lawson, Joe
    Dearden, Lindsay
    McQuarrie, Kelly
    Espina, Byron M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (30)
  • [28] Phase 1 efficacy and pharmacodynamic results of exicorilant plus enzalutamide in patients with metastatic castration-resistant prostate cancer.
    Morris, Michael J.
    Linch, Mark David
    Crabb, Simon J.
    Beer, Tomasz M.
    Heath, Elisabeth I.
    Gordon, Michael S.
    De Bono, Johann S.
    Pashova, Hristina I.
    Tudor, Iulia Cristina
    Greenstein, Andrew E.
    Mann, Grace
    Liu, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [29] transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer.
    Scher, Howard I.
    Mccormack, Robert Thomas
    Molina, Arturo
    Smith, Matthew Raymond
    Dreicer, Robert
    Saad, Fred
    De Wit, Ronald
    Fizazi, Karim
    Aftab, Dana T.
    Limon, Ana
    Fleisher, Martin
    De Bono, Johann S.
    Kelloff, Gary J.
    Heller, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [30] A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
    Dhawan, Mallika Sachdev
    Lee, Mina
    Bryce, Alan H.
    Weinberg, Vivian K.
    Ryan, Charles J.
    Derleth, Christina Louise
    Harzstark, Andrea Lynne
    Small, Eric Jay
    Aggarwal, Rahul Raj
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
12345